From the FY17 report released on 28/8/17 Results for...

From the FY17 report released on 28/8/17
Results for announcement to the market $’000
Revenue from continuing operations (Appendix 4E item 2.1) Down 18% to $3,643,000
Loss from continuing operations after tax attributable to members (Appendix 4E item 2.2) Down (decrease) 29% to $15,217 Profit for the period attributable to members (Appendix 4E item 2.3) Up (increase from loss in pcp) 136% to $8,200 D

Explanation of Revenue (Appendix 4E item 2.6) Revenue from continuing operations of $3,643,000 (2016: $4,446,000) reflects licensing, royalty and research revenue from commercial partners, including milestone payments from AstraZeneca under a drug delivery license agreement. Interest income on cash invested of $651,000 (2016: $679,000) is also included.

Can someone please tell me why there is 18% decrease in revenue comparing to FY16?
Also,  when is the royalty from Vivagel condom starts to roll in? Do we have a forecast?

Looking to increase holding, but would like to ensure a good margin of safety.

Thanks.